{"entity":{"type":"insider","cik":"0001385112","url":"/insider/0001385112","json_url":"/insider/0001385112.json","name":"Aviezer David","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":13,"n_filings":5,"first":"2009-04-20","last":"2012-05-04","span_basis":"filed_date"},"name_variants":[{"name":"Aviezer David","source":"filing","n_filings":5,"first_seen":"2009-04-20","last_seen":"2012-05-04"}],"transactions":[{"id":3508854,"accession":"0001144204-12-026347","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-12-026347","line_url":"/filing/0001144204-12-026347#line-3","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385112","owner_name":"Aviezer David","owner_display_name":"Aviezer David","owner_url":"/insider/0001385112","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":450000.0,"shares_display":"450,000","price_per_share":7.13,"price_display":"7.13","price_state":"stated","total_value":3208500.0,"total_display":"3,208,500.00","total_whole":"3,208,500","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-05-02","filed_date":"2012-05-04","scope":"insider"},{"id":6018545,"accession":"0001209191-09-049447","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-09-049447","line_url":"/filing/0001209191-09-049447#line-5","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385112","owner_name":"Aviezer David","owner_display_name":"Aviezer David","owner_url":"/insider/0001385112","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34238.0,"shares_display":"34,238","price_per_share":9.36,"price_display":"9.36","price_state":"stated","total_value":320467.68,"total_display":"320,467.68","total_whole":"320,468","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-10-21","filed_date":"2009-10-21","scope":"insider"},{"id":6018535,"accession":"0001209191-09-049447","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-09-049447","line_url":"/filing/0001209191-09-049447#line-2","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385112","owner_name":"Aviezer David","owner_display_name":"Aviezer David","owner_url":"/insider/0001385112","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60000.0,"shares_display":"60,000","price_per_share":9.45,"price_display":"9.45","price_state":"stated","total_value":567000.0,"total_display":"567,000.00","total_whole":"567,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-10-20","filed_date":"2009-10-21","scope":"insider"},{"id":6018532,"accession":"0001209191-09-049447","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-049447","line_url":"/filing/0001209191-09-049447#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385112","owner_name":"Aviezer David","owner_display_name":"Aviezer David","owner_url":"/insider/0001385112","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":150000.0,"shares_display":"150,000","price_per_share":9.43,"price_display":"9.43","price_state":"stated","total_value":1414500.0,"total_display":"1,414,500.00","total_whole":"1,414,500","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-10-19","filed_date":"2009-10-21","scope":"insider"},{"id":5664129,"accession":"0001209191-09-026022","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-09-026022","line_url":"/filing/0001209191-09-026022#line-5","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385112","owner_name":"Aviezer David","owner_display_name":"Aviezer David","owner_url":"/insider/0001385112","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":55900.0,"shares_display":"55,900","price_per_share":3.41,"price_display":"3.41","price_state":"stated","total_value":190619.0,"total_display":"190,619.00","total_whole":"190,619","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-05-12","filed_date":"2009-05-12","scope":"insider"},{"id":5664126,"accession":"0001209191-09-026022","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-09-026022","line_url":"/filing/0001209191-09-026022#line-2","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385112","owner_name":"Aviezer David","owner_display_name":"Aviezer David","owner_url":"/insider/0001385112","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":38900.0,"shares_display":"38,900","price_per_share":3.41,"price_display":"3.41","price_state":"stated","total_value":132649.0,"total_display":"132,649.00","total_whole":"132,649","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-05-11","filed_date":"2009-05-12","scope":"insider"},{"id":5664125,"accession":"0001209191-09-026022","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-026022","line_url":"/filing/0001209191-09-026022#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385112","owner_name":"Aviezer David","owner_display_name":"Aviezer David","owner_url":"/insider/0001385112","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5200.0,"shares_display":"5,200","price_per_share":3.4,"price_display":"3.40","price_state":"stated","total_value":17680.0,"total_display":"17,680.00","total_whole":"17,680","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-05-08","filed_date":"2009-05-12","scope":"insider"},{"id":5902479,"accession":"0001209191-09-024860","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-09-024860","line_url":"/filing/0001209191-09-024860#line-5","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385112","owner_name":"Aviezer David","owner_display_name":"Aviezer David","owner_url":"/insider/0001385112","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":3.01,"price_display":"3.01","price_state":"stated","total_value":60200.0,"total_display":"60,200.00","total_whole":"60,200","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-05-06","filed_date":"2009-05-06","scope":"insider"},{"id":5902473,"accession":"0001209191-09-024860","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-09-024860","line_url":"/filing/0001209191-09-024860#line-2","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385112","owner_name":"Aviezer David","owner_display_name":"Aviezer David","owner_url":"/insider/0001385112","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21600.0,"shares_display":"21,600","price_per_share":3.07,"price_display":"3.07","price_state":"stated","total_value":66312.0,"total_display":"66,312.00","total_whole":"66,312","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-05-05","filed_date":"2009-05-06","scope":"insider"},{"id":5902471,"accession":"0001209191-09-024860","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-024860","line_url":"/filing/0001209191-09-024860#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385112","owner_name":"Aviezer David","owner_display_name":"Aviezer David","owner_url":"/insider/0001385112","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":33400.0,"shares_display":"33,400","price_per_share":3.01,"price_display":"3.01","price_state":"stated","total_value":100534.0,"total_display":"100,534.00","total_whole":"100,534","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-05-04","filed_date":"2009-05-06","scope":"insider"},{"id":5883810,"accession":"0001209191-09-022177","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-09-022177","line_url":"/filing/0001209191-09-022177#line-5","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385112","owner_name":"Aviezer David","owner_display_name":"Aviezer David","owner_url":"/insider/0001385112","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":33300.0,"shares_display":"33,300","price_per_share":2.51,"price_display":"2.51","price_state":"stated","total_value":83583.0,"total_display":"83,583.00","total_whole":"83,583","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-04-20","filed_date":"2009-04-20","scope":"insider"},{"id":5883803,"accession":"0001209191-09-022177","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-09-022177","line_url":"/filing/0001209191-09-022177#line-2","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385112","owner_name":"Aviezer David","owner_display_name":"Aviezer David","owner_url":"/insider/0001385112","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":2.56,"price_display":"2.56","price_state":"stated","total_value":25600.0,"total_display":"25,600.00","total_whole":"25,600","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-04-17","filed_date":"2009-04-20","scope":"insider"},{"id":5883801,"accession":"0001209191-09-022177","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-022177","line_url":"/filing/0001209191-09-022177#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385112","owner_name":"Aviezer David","owner_display_name":"Aviezer David","owner_url":"/insider/0001385112","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6700.0,"shares_display":"6,700","price_per_share":2.5,"price_display":"2.50","price_state":"stated","total_value":16750.0,"total_display":"16,750.00","total_whole":"16,750","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-04-16","filed_date":"2009-04-20","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":13,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":13,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":13},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001006281","name":"Protalix BioTherapeutics, Inc.","url":"/issuer/0001006281","role":"Director, Officer (President & CEO)","n_filings":5,"first_seen":"2009-04-20","last_seen":"2012-05-04"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001385112","retrieved_at":"2026-08-24T19:40:25+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}